all the information, none of the junk | biotech • healthcare • life sciences

Genmab Expands SeaGen Alliance

Xconomy Seattle — 

Genmab, the Denmark-based developer of antibody drugs, said today it has formed  a second collaboration to use technology from Seattle Genetics (NASDAQ: SGEN) that’s designed to make antibodies more potent. Genmab will seek use the “empowered antibody” technology against a target known as CD74, which is found on various blood cancer and solid tumor cells. Seattle Genetics is getting an undisclosed upfront payment, and will have the right to co-develop and co-market the drug candidate after Genmab completes the first phase of clinical trials.